ANAB Stock Overview
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$23.12|
|52 Week High||US$37.89|
|52 Week Low||US$18.20|
|1 Month Change||20.48%|
|3 Month Change||-8.51%|
|1 Year Change||-12.56%|
|3 Year Change||-59.02%|
|5 Year Change||-3.39%|
|Change since IPO||36.00%|
Recent News & Updates
Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders, with the analysts delivering a...
|ANAB||US Biotechs||US Market|
Return vs Industry: ANAB exceeded the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: ANAB exceeded the US Market which returned -20.5% over the past year.
|ANAB Average Weekly Movement||9.6%|
|Biotechs Industry Average Movement||12.9%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.5%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: ANAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ANAB's weekly volatility (10%) has been stable over the past year.
About the Company
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
AnaptysBio Fundamentals Summary
|ANAB fundamental statistics|
Is ANAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANAB income statement (TTM)|
|Cost of Revenue||US$96.83m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.69|
|Net Profit Margin||-143.46%|
How did ANAB perform over the long term?See historical performance and comparison
Is ANAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ANAB?
Other financial metrics that can be useful for relative valuation.
|What is ANAB's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ANAB's PS Ratio compare to its peers?
|ANAB PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: ANAB is good value based on its Price-To-Sales Ratio (12.3x) compared to the peer average (49.1x).
Price to Earnings Ratio vs Industry
How does ANAB's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Sales vs Industry: ANAB is good value based on its Price-To-Sales Ratio (12.3x) compared to the US Biotechs industry average (13.8x)
Price to Sales Ratio vs Fair Ratio
What is ANAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||12.3x|
|Fair PS Ratio||0.9x|
Price-To-Sales vs Fair Ratio: ANAB is expensive based on its Price-To-Sales Ratio (12.3x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).
Share Price vs Fair Value
What is the Fair Price of ANAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ANAB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ANAB's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANAB's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is AnaptysBio forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANAB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ANAB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ANAB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ANAB's revenue (17.7% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: ANAB's revenue (17.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ANAB is forecast to be unprofitable in 3 years.
Discover growth companies
How has AnaptysBio performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANAB is currently unprofitable.
Growing Profit Margin: ANAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANAB is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.
Accelerating Growth: Unable to compare ANAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: ANAB has a negative Return on Equity (-22.94%), as it is currently unprofitable.
Discover strong past performing companies
How is AnaptysBio's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ANAB's short term assets ($512.4M) exceed its short term liabilities ($19.8M).
Long Term Liabilities: ANAB's short term assets ($512.4M) exceed its long term liabilities ($274.6M).
Debt to Equity History and Analysis
Debt Level: ANAB is debt free.
Reducing Debt: ANAB has no debt compared to 5 years ago when its debt to equity ratio was 12.7%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANAB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ANAB has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 13.3% each year
Discover healthy companies
What is AnaptysBio current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANAB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ANAB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dan Faga (41 yo)
Mr. Daniel R. Faga, also known as Dan, is Director of Affini-T Therapeutics, Inc. from April 2022. He serves as Director at AnaptysBio, Inc. since November 2021 and serves as Interim President and Chief Ex...
Experienced Management: ANAB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: ANAB's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.
AnaptysBio, Inc.'s employee growth, exchange listings and data sources
- Name: AnaptysBio, Inc.
- Ticker: ANAB
- Exchange: NasdaqGS
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$651.662m
- Shares outstanding: 28.19m
- Website: https://www.anaptysbio.com
Number of Employees
- AnaptysBio, Inc.
- 10770 Wateridge Circle
- Suite 210
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.